To establish a connection between BCR-ABL signalling and PRL-3 expression, we treated human CML cell lines, K562 and KCL-22 cells with Imatinib and assessed the expression of PRL-3. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.